The company expects to grant a 30-day option to the underwriters to purchase up to an additional 15% of the shares offered solely to cover over-allotments. All of the shares are being sold by Natus Medical.
All of the shares are being offered by Cowen and Company, and UBS Investment Bank as joint bookrunning managers. Natixis Bleichroeder, Needham & Company, Raymond James & Associates, and Roth Capital Partners, are acting as co-managers.